You are here

Novel cancer drug stymied by rigid billing system

The problem is that there is no billing code for the US$373,000 Yescarta therapy in Medicare


A US government reimbursement system that does not fully cover the costs for Gilead Sciences Inc's complex blood cancer therapy is partly to blame for the slow uptake of the novel life-saving treatment, according to doctors who are trying to treat patients.

Only a...

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to